CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Core Insights - CRISPR Therapeutics is positioned for significant advancements in 2025, with multiple key updates expected across its clinical and commercial portfolio, particularly with the ongoing launch of CASGEVY® and updates on various product candidates [1][2][3] Product Development and Pipeline - The ongoing launch of CASGEVY® is gaining momentum, with over 50 authorized treatment centers activated globally and more than 50 patients having undergone cell collection by the end of 2024; significant growth in new patient collections is anticipated in 2025 [1][3] - Clinical trials for next-generation CAR T product candidates, CTX112™ and CTX131™, are ongoing, targeting CD19 and CD70 across multiple indications, with updates expected in mid-2025 [1][5] - A global strategic partnership has been established with Nkure Therapeutics to co-develop and co-commercialize CTX112 in India, aiming to accelerate its development in regions with unmet medical needs [1][5] - Clinical trials for in vivo gene editing product candidates, CTX310™ and CTX320™, targeting ANGPTL3 and LPA respectively, are ongoing, with updates expected in the first half of 2025 [1][12] Financial Performance - As of December 31, 2024, the company reported a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities, an increase from$1.7 billion at the end of 2023 [1][20] - Research and development expenses for Q4 2024 were $82.2 million, a decrease from$95.1 million in Q4 2023, primarily due to reduced external research and manufacturing costs [10] - The net loss for Q4 2024 was $37.3 million, compared to a net income of$89.3 million in Q4 2023, reflecting changes in revenue and expenses [10][19]